Last 12 months
Inside the activity.
0 purchase rows · 55 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 11 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 15 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 15 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 14 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2021 Filed Dec 4, 2021 00:08 UTC Amendment |
French Glendon E. IIIDirector · President and CEO
|
SaleCommon Stock | 19,941 | $42.19 | $841,310.79 |
DisclosureSEC source: 0001209191-21-067997 · doc4a.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,234,884 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.85 to $42.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2021 Filed Dec 4, 2021 00:08 UTC Amendment |
French Glendon E. IIIDirector · President and CEO
|
SaleCommon Stock | 5,059 | $41.01 | $207,469.59 |
DisclosureSEC source: 0001209191-21-067997 · doc4a.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,254,825 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.71 to $41.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2021 Filed Dec 4, 2021 00:08 UTC Amendment |
French Glendon E. IIIDirector · President and CEO
|
Exercise / conversionCommon Stock | 10,000 | $2.20 | $22,000.00 |
DisclosureSEC source: 0001209191-21-067997 · doc4a.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,259,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2021 Filed May 19, 2021 21:19 UTC |
Rose Geoffrey BeranChief Commercial Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 49,428 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001209191-21-034061 · doc4.xml · derivative · entry 2 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,428 shares Expires 2025-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| May 18, 2021 Filed May 19, 2021 21:19 UTC |
Rose Geoffrey BeranChief Commercial Officer
|
Exercise / conversionCommon Stock | 49,428 | $1.40 | $69,199.20 |
DisclosureSEC source: 0001209191-21-034061 · doc4.xml · nonDerivative · entry 1 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2021 Filed May 11, 2021 22:58 UTC |
Rose Geoffrey BeranChief Commercial Officer
|
SaleCommon Stock | 1 | $42.51 | $42.51 |
DisclosureSEC source: 0001209191-21-031854 · doc4.xml · nonDerivative · entry 4 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,673 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. Read SEC document |
| May 10, 2021 Filed May 11, 2021 22:58 UTC |
Rose Geoffrey BeranChief Commercial Officer
|
SaleCommon Stock | 118 | $42.25 | $4,985.50 |
DisclosureSEC source: 0001209191-21-031854 · doc4.xml · nonDerivative · entry 3 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,674 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. Read SEC document |
| May 10, 2021 Filed May 11, 2021 22:58 UTC |
Rose Geoffrey BeranChief Commercial Officer
|
SaleCommon Stock | 900 | $41.47 | $37,323.00 |
DisclosureSEC source: 0001209191-21-031854 · doc4.xml · nonDerivative · entry 2 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,792 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.02 to $41.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 10, 2021 Filed May 11, 2021 22:58 UTC |
Rose Geoffrey BeranChief Commercial Officer
|
SaleCommon Stock | 3,778 | $40.47 | $152,895.66 |
DisclosureSEC source: 0001209191-21-031854 · doc4.xml · nonDerivative · entry 1 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,692 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 21:26 UTC |
Rose Geoffrey BeranChief Commercial Officer
|
SaleCommon Stock | 4,797 | $43.24 | $207,422.28 |
DisclosureSEC source: 0001209191-21-027833 · doc4.xml · nonDerivative · entry 1 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,470 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.83 to $43.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 21:03 UTC |
French Glendon E. IIIDirector · President and CEO
|
SaleCommon Stock | 1,000 | $43.70 | $43,700.00 |
DisclosureSEC source: 0001209191-21-026985 · doc4.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 27,571 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Glendon E. French III Children's Irrevocable Trust on December 15, 2020. F5 · ownership.nature: The shares are directly held by the Glendon E. French III Children's Irrevocable Trust dated 11-17-98 for which the Reporting Person is a trustee. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 21:03 UTC |
French Glendon E. IIIDirector · President and CEO
|
SaleCommon Stock | 5,011 | $44.21 | $221,536.31 |
DisclosureSEC source: 0001209191-21-026985 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,224,884 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.13 to $44.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 21:03 UTC |
French Glendon E. IIIDirector · President and CEO
|
SaleCommon Stock | 19,989 | $43.64 | $872,319.96 |
DisclosureSEC source: 0001209191-21-026985 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,229,895 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.12 to $44.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 15, 2021 Filed Dec 3, 2021 23:46 UTC Amendment |
French Glendon E. IIIDirector · President and CEO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001209191-21-067978 · doc4a.xml · derivative · entry 4 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,999 Underlying: Common Stock · 25,000 shares Expires 2030-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are immediately exercisable and vest in 48 equal monthly installments beginning on August 28, 2020, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| April 15, 2021 Filed Dec 3, 2021 23:46 UTC Amendment |
French Glendon E. IIIDirector · President and CEO
|
SaleCommon Stock | 5,011 | $44.21 | $221,536.31 |
DisclosureSEC source: 0001209191-21-067978 · doc4a.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,249,884 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.13 to $44.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 15, 2021 Filed Dec 3, 2021 23:46 UTC Amendment |
French Glendon E. IIIDirector · President and CEO
|
SaleCommon Stock | 19,989 | $43.64 | $872,319.96 |
DisclosureSEC source: 0001209191-21-067978 · doc4a.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,254,895 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.12 to $44.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 15, 2021 Filed Dec 3, 2021 23:46 UTC Amendment |
French Glendon E. IIIDirector · President and CEO
|
Exercise / conversionCommon Stock | 25,000 | $2.20 | $55,000.00 |
DisclosureSEC source: 0001209191-21-067978 · doc4a.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,274,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2021 Filed Apr 6, 2021 23:40 UTC |
Sung DerrickChief Financial Officer
|
SaleCommon Stock | 600 | $48.33 | $28,998.00 |
DisclosureSEC source: 0001209191-21-025747 · doc4.xml · nonDerivative · entry 5 Sung Derrick · CIK 0001670118 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.305 to $48.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 06, 2021 Filed Apr 6, 2021 23:40 UTC |
Sung DerrickChief Financial Officer
|
SaleCommon Stock | 1,575 | $47.79 | $75,269.25 |
DisclosureSEC source: 0001209191-21-025747 · doc4.xml · nonDerivative · entry 4 Sung Derrick · CIK 0001670118 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,259 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.29 to $48.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 06, 2021 Filed Apr 6, 2021 23:40 UTC |
Sung DerrickChief Financial Officer
|
SaleCommon Stock | 2,825 | $46.49 | $131,334.25 |
DisclosureSEC source: 0001209191-21-025747 · doc4.xml · nonDerivative · entry 3 Sung Derrick · CIK 0001670118 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,834 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.162 to $46.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:20 UTC |
BOSTON SCIENTIFIC CORP10% owner
|
SaleCommon Stock | 650,000 | $43.60 | $28,340,000.00 |
DisclosureSEC source: 0001225208-21-006650 · doc4.xml · nonDerivative · entry 1 BOSTON SCIENTIFIC CORP · CIK 0000885725 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,988,106 F1 · kind: These shares of the Issuer's common stock were sold in a block order at a price of $43.60. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 23:41 UTC |
Rose Geoffrey BeranChief Commercial Officer
|
SaleCommon Stock | 266 | $48.46 | $12,890.36 |
DisclosureSEC source: 0001209191-21-025748 · doc4.xml · nonDerivative · entry 2 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,064 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.11 to $48.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 23:41 UTC |
Rose Geoffrey BeranChief Commercial Officer
|
SaleCommon Stock | 4,531 | $47.59 | $215,630.29 |
DisclosureSEC source: 0001209191-21-025748 · doc4.xml · nonDerivative · entry 1 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,330 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.08 to $48.045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 23:40 UTC |
Sung DerrickChief Financial Officer
|
SaleCommon Stock | 220 | $48.56 | $10,683.20 |
DisclosureSEC source: 0001209191-21-025747 · doc4.xml · nonDerivative · entry 2 Sung Derrick · CIK 0001670118 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.435 to $48.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 23:40 UTC |
Sung DerrickChief Financial Officer
|
SaleCommon Stock | 4,780 | $47.56 | $227,336.80 |
DisclosureSEC source: 0001209191-21-025747 · doc4.xml · nonDerivative · entry 1 Sung Derrick · CIK 0001670118 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,879 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.08 to $48.045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 05, 2021 Filed Apr 8, 2021 01:05 UTC Amendment |
Rose Geoffrey BeranChief Commercial Officer
|
SaleCommon Stock | 319 | $48.43 | $15,449.17 |
DisclosureSEC source: 0001209191-21-025997 · doc4a.xml · nonDerivative · entry 2 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,267 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.09 to $48.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 05, 2021 Filed Apr 8, 2021 01:05 UTC Amendment |
Rose Geoffrey BeranChief Commercial Officer
|
SaleCommon Stock | 4,478 | $47.59 | $213,108.02 |
DisclosureSEC source: 0001209191-21-025997 · doc4a.xml · nonDerivative · entry 1 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,586 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.08 to $48.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 20:24 UTC |
BOSTON SCIENTIFIC CORP10% owner
|
SaleCommon Stock | 1,350,000 | $40.80 | $55,080,000.00 |
DisclosureSEC source: 0001225208-21-006217 · doc4.xml · nonDerivative · entry 1 BOSTON SCIENTIFIC CORP · CIK 0000885725 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,638,106 F1 · kind: These shares of the Issuer's common stock were sold in a block order at a price of $40.80. Read SEC document |
| December 10, 2020 Filed Apr 8, 2021 22:11 UTC |
Rose Geoffrey BeranChief Commercial Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001209191-21-026141 · doc5.xml · derivative · entry 2 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,428 Underlying: Common Stock · 22,000 shares Expires 2025-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| December 10, 2020 Filed Apr 8, 2021 22:11 UTC |
Rose Geoffrey BeranChief Commercial Officer
|
Exercise / conversionCommon Stock | 22,000 | $1.40 | $30,800.00 |
DisclosureSEC source: 0001209191-21-026141 · doc5.xml · nonDerivative · entry 1 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 22:46 UTC |
BOSTON SCIENTIFIC CORP10% owner
|
ConversionSeries G-1 Preferred Stock · Derivative | 2,081,909 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012257 · doc4.xml · derivative · entry 14 BOSTON SCIENTIFIC CORP · CIK 0000885725 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,081,909 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 22:46 UTC |
BOSTON SCIENTIFIC CORP10% owner
|
ConversionSeries F-1 Preferred Stock · Derivative | 3,787,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012257 · doc4.xml · derivative · entry 13 BOSTON SCIENTIFIC CORP · CIK 0000885725 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,787,878 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 22:46 UTC |
BOSTON SCIENTIFIC CORP10% owner
|
ConversionSeries E-1 Preferred Stock · Derivative | 6,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012257 · doc4.xml · derivative · entry 12 BOSTON SCIENTIFIC CORP · CIK 0000885725 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,215 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 22:46 UTC |
BOSTON SCIENTIFIC CORP10% owner
|
ConversionSeries D-1 Preferred Stock · Derivative | 542 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012257 · doc4.xml · derivative · entry 11 BOSTON SCIENTIFIC CORP · CIK 0000885725 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 542 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 22:46 UTC |
BOSTON SCIENTIFIC CORP10% owner
|
ConversionSeries C-1 Preferred Stock · Derivative | 23,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012257 · doc4.xml · derivative · entry 10 BOSTON SCIENTIFIC CORP · CIK 0000885725 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,180 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 22:46 UTC |
BOSTON SCIENTIFIC CORP10% owner
|
ConversionSeries B-1 Preferred Stock · Derivative | 47,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012257 · doc4.xml · derivative · entry 9 BOSTON SCIENTIFIC CORP · CIK 0000885725 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,536 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 22:46 UTC |
BOSTON SCIENTIFIC CORP10% owner
|
ConversionSeries A-1 Preferred Stock · Derivative | 40,705 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012257 · doc4.xml · derivative · entry 8 BOSTON SCIENTIFIC CORP · CIK 0000885725 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,705 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 22:46 UTC |
BOSTON SCIENTIFIC CORP10% owner
|
ConversionCommon Stock | 542 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012257 · doc4.xml · nonDerivative · entry 7 BOSTON SCIENTIFIC CORP · CIK 0000885725 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,988,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 22:46 UTC |
BOSTON SCIENTIFIC CORP10% owner
|
ConversionCommon Stock | 6,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012257 · doc4.xml · nonDerivative · entry 6 BOSTON SCIENTIFIC CORP · CIK 0000885725 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,987,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 22:46 UTC |
BOSTON SCIENTIFIC CORP10% owner
|
ConversionCommon Stock | 23,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012257 · doc4.xml · nonDerivative · entry 5 BOSTON SCIENTIFIC CORP · CIK 0000885725 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,981,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 22:46 UTC |
BOSTON SCIENTIFIC CORP10% owner
|
ConversionCommon Stock | 40,705 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012257 · doc4.xml · nonDerivative · entry 4 BOSTON SCIENTIFIC CORP · CIK 0000885725 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,958,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 22:46 UTC |
BOSTON SCIENTIFIC CORP10% owner
|
ConversionCommon Stock | 47,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012257 · doc4.xml · nonDerivative · entry 3 BOSTON SCIENTIFIC CORP · CIK 0000885725 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,917,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 22:46 UTC |
BOSTON SCIENTIFIC CORP10% owner
|
ConversionCommon Stock | 2,081,909 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012257 · doc4.xml · nonDerivative · entry 2 BOSTON SCIENTIFIC CORP · CIK 0000885725 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,869,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 22:46 UTC |
BOSTON SCIENTIFIC CORP10% owner
|
ConversionCommon Stock | 3,787,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-012257 · doc4.xml · nonDerivative · entry 1 BOSTON SCIENTIFIC CORP · CIK 0000885725 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,788,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 20:16 UTC |
Ferrari RichardDirector
|
ConversionSeries G-1 Preferred Stock · Derivative | 3,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-014287 · wf-form4_160192897069111.xml · derivative · entry 13 FERRARI RICHARD M · CIK 0001034413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,030 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 20:16 UTC |
Ferrari RichardDirector
|
ConversionSeries E-1 Preferred Stock · Derivative | 65,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-014287 · wf-form4_160192897069111.xml · derivative · entry 12 FERRARI RICHARD M · CIK 0001034413 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 65,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The shares are directly held by De Novo Ventures III Liquidating Trust ("De Novo"). The Reporting Person, along with Fred Dozier and Joseph Mandato, and Jay Watkins are the trustees of De Novo and exercise shares voting and dispositie control over the shares held by De Novo Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 20:16 UTC |
Ferrari RichardDirector
|
ConversionSeries D-1 Preferred Stock · Derivative | 126,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-014287 · wf-form4_160192897069111.xml · derivative · entry 11 FERRARI RICHARD M · CIK 0001034413 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 126,603 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The shares are directly held by De Novo Ventures III Liquidating Trust ("De Novo"). The Reporting Person, along with Fred Dozier and Joseph Mandato, and Jay Watkins are the trustees of De Novo and exercise shares voting and dispositie control over the shares held by De Novo Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 20:16 UTC |
Ferrari RichardDirector
|
ConversionSeries C-1 Preferred Stock · Derivative | 327,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-014287 · wf-form4_160192897069111.xml · derivative · entry 10 FERRARI RICHARD M · CIK 0001034413 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 327,560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The shares are directly held by De Novo Ventures III Liquidating Trust ("De Novo"). The Reporting Person, along with Fred Dozier and Joseph Mandato, and Jay Watkins are the trustees of De Novo and exercise shares voting and dispositie control over the shares held by De Novo Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 20:16 UTC |
Ferrari RichardDirector
|
ConversionSeries B-1 Preferred Stock · Derivative | 675,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-014287 · wf-form4_160192897069111.xml · derivative · entry 9 FERRARI RICHARD M · CIK 0001034413 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 675,227 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The shares are directly held by De Novo Ventures III Liquidating Trust ("De Novo"). The Reporting Person, along with Fred Dozier and Joseph Mandato, and Jay Watkins are the trustees of De Novo and exercise shares voting and dispositie control over the shares held by De Novo Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 20:16 UTC |
Ferrari RichardDirector
|
ConversionSeries A-1 Preferred Stock · Derivative | 26,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-014287 · wf-form4_160192897069111.xml · derivative · entry 8 FERRARI RICHARD M · CIK 0001034413 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 26,266 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The shares are directly held by De Novo Ventures III Liquidating Trust ("De Novo"). The Reporting Person, along with Fred Dozier and Joseph Mandato, and Jay Watkins are the trustees of De Novo and exercise shares voting and dispositie control over the shares held by De Novo Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.